GIP Effects at Insulin Induced Hypoglycemia in Patients With Type 2 Diabetes

Effects of Glucose-dependent Insulinotropic Polypeptide at Insulin Induced Hypoglycemia in Patients With Type 2 Diabetes

Status

Completed

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01414556

Acronym

GIP-HYPO-T2DM

Enrollment

Registered

2011-08-11

Start date

2011-05-31

Completion date

2012-11-30

Last updated

2013-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Brief summary

Investigation of GIP effects at fasting and hypoglycemia

Interventions

OTHERGlucose-dependent Insulinotropic polypeptide

infusion 4 pmol x kg x min first 15 min, thereafter 2 pmol x kg x min

OTHERsaline

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

MALE

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Caucasians 18 years or older with Type 2 diabetes (WHO criteria)

Exclusion criteria

* HbA1c \>9 % * Liver disease (ALAT/ASAT \>2 x upper normal limit) * Diabetic nephropathy (s-creatinine \>130 µM or albuminuria) * Proliferative diabetic retinopathy (anamnestic) * Severe arteriosclerosis or heart failure (NYHA group III og IV) * Anemia * treatment with medication not applicable to pause for 12 hours * Fasting plasma glucose \>15 mM on screening day.

Design outcomes

Primary

Measure	Time frame
glucagon/insulin(c-peptide) absolute, incremental and area under curve values	approx. 15 minutes intervals, time 0 to 120 min

Secondary

Measure	Time frame
plasma gut hormones and nutrients	approx. 15 minutes intervals, time 0 to 120 min

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026